Primary objectives:
-Characterize the safety and tolerability of TEV-56278
-Determine the Recommended Phase 2 Dose (RP2D)
-Evaluate antitumor activity of TEV-56278 -Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab
-Determine a RP2D of TEV-56278 in combination with pembrolizumab